BIAFW — bioAffinity Technologies, Inc.

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1712762 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,070,280 -43,896 -3,510,672 -5,277,023 7,553,671 2,550,034 3,639,110
Jun 2026 1,510,579 422,742 -3,334,864 -3,366,082 7,619,279 2,429,719 3,850,482
Mar 2026 1,351,527 422,891 -3,616,976 -3,630,610 7,945,252 3,098,366 4,283,866
Dec 2025 1,538,813 638,687 -3,190,963 -3,137,466 10,960,772 6,449,782 3,683,116

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-11,468,205
Investing CF
$-91,988
Financing CF
$13,187,077
CapEx
$-109,061
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-75,550,756
Inventory
$82,378
Receivables
$894,823
ST Investments
—
EBIT TTM
$-15,134,042
Pretax Income TTM
$-15,178,879
Interest Exp TTM
$44,837
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,900,985
EBITDA
$-11,968,556
Free Cash Flow
$-6,909,285
Enterprise Value
—
Total Cash
$2,429,719
Total Debt
$1,435,005
Shares Out
—
Trailing EPS
—
Book Value
$24.29
ROE
-1860.2%
ROA
-125.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 6,107,959 -10,626,508 -14,909,754 10,960,772 3,683,116 7,277,656 -9,328,842
Dec 2024 9,362,022 -8,953,445 -9,039,831 6,513,667 3,911,631 2,602,036 -7,264,795
Dec 2023 2,532,499 -7,973,228 -7,937,011 8,221,552 3,366,297 4,855,255 -6,037,806
Dec 2022 4,803 -4,011,058 -8,154,113 12,182,125 1,138,682 11,043,443 -4,070,845

TTM Snapshot

Revenues TTM
$5,900,985
NetIncome TTM
$-15,185,242
OpCashFlow TTM
—
Assets (Latest)
$7,619,279
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
IDXX IDEXX LABORATORIES INC /DE $54.38B $690.24 —
IQV IQVIA HOLDINGS INC. $42.45B $257.60 —
INCY INCYTE CORP $24.27B $119.09 —
MEDP Medpace Holdings, Inc. $18.27B $653.09 —
CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. $15.92B $332.16 —

News headlines (Yahoo Finance, 1h cache)

BIAF Stock Dips Post Q3 Earnings Despite Rising Test Demand, Sales Down
2026-11-13 15:22 · Yahoo
bioAffinity Technologies CEO: Record CyPath Lung testing fuels growth ambitions
2026-11-11 18:35 · Yahoo
bioAffinity Technologies posts record monthly volume for CyPath Lung test
2026-11-11 15:02 · Yahoo
bioAffinity posts record month for CyPath Lung cancer test
2026-11-11 13:37 · Yahoo
bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test
2026-11-11 13:00 · Yahoo
bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization
2026-11-06 22:40 · Yahoo
bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
2026-10-29 12:00 · Yahoo
bioAffinity Technologies expands Lung diagnostics pipeline into COPD and Asthma
2026-10-27 15:17 · Yahoo
bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
2026-10-15 12:00 · Yahoo
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
2026-10-13 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.